MarketPulse

oncology therapeutics

2 articles
The Motley FoolThe Motley Fool··Pamela Kock

Nuvation Bio Executive Liquidates $904K in Stock; Retains Substantial Position

Nuvation Bio's Chief Regulatory Officer sold 200,000 shares for $904K but retained 53,000 shares and 700,000 options, suggesting routine profit-taking rather than lost confidence.
NUVBbiotechclinical-stage
The Motley FoolThe Motley Fool··Jonathan Ponciano

Oncology Biotech Syndax Surges on $6.5M Investment Amid 629% Revenue Spike

Syndax Pharmaceuticals attracted $6.54M institutional investment as its approved cancer therapies generated $172.4M revenue, up 629% year-over-year, driving 80%+ stock surge.
SNDXrevenue growthcancer treatment